AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 152 min read$COGT

Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027

Cogent Biosciences (COGT) announced FDA acceptance of its NDA for Bezuclastinib to treat Advanced Systemic Mastocytosis, with a PDUFA target date of June 2027. The NDA is supported by APEX trial data showing a 65% overall response rate and 79% 12-month progression-free survival. The FDA has not identified any review issues. COGT is also advancing NDAs for other indications. The stock is currently trading at $33.49, up 0.24%.

Original reporting
rttnews.com
Published Sep 15, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027 — source image
Source · rttnews.com
Decision brief

The 30-second read

$COGTBullishHigh
01

Why it matters

The NDA acceptance signals a near-term catalyst that could drive significant stock movement.

02

Market read

Regulatory milestone for a rare disease therapy; high relevance for biotech traders.

03

What to watch

Potential competition from other mastocytosis therapies and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: today

Background

Cogent Biosciences is a clinical-stage biotech focusing on KIT-driven diseases.

Company-level read

Ticker impact

$COGTBullishHigh confidence
Context

FDA accepted Cogent Biosciences' NDA for Bezuclastinib, providing trial data and a PDUFA date.

Expected impact

Short-term upside as investors price in potential approval.

Evidence & confidence

First report of NDA acceptance and strong trial results; biotech stocks react strongly to FDA milestones.

Market effects

Sector

May lift other KIT inhibitor developers and rare disease biotech sector.

Regional

Positive for US biotech market.

Global

Limited to biotech investors worldwide.

Counterpoint

What could challenge this read

Approval is not guaranteed; FDA may request additional data, risking a pullback.

Key entities

  • company
    Cogent Biosciences Inc.

    Biotech developing Bezuclastinib for advanced systemic mastocytosis.

  • regulator
    FDA

    U.S. Food and Drug Administration reviewing the NDA.

Read at source← All news

Related articles

AUG 10
$COGTMed

Cogent Biosciences, Inc. (COGT): Results of Operations and Financial Condition

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Applicatio

SEC EDGAR 8-K6 min
SEP 15
$RCKTHighAI 8/10

Rocket Gets FDA Nod To Advance RP-A501 Phase 2 Trial In Danon Disease; Stock Up

Rocket Pharmaceuticals (RCKT) received FDA alignment to continue its Phase 2 trial for RP-A501 in Danon disease, with a recalibrated dose and modified protocol. The trial will include 12 male patients, with dosing expected to complete by mid-2027. The FDA reviewed safety data from the first three patients, finding no adverse events. RCKT's stock rose 2.39% to $3.43 on Monday.

rttnews.com2 min
SEP 15
$KMBHighAI 9/10

Kimberly-Clark Moves to Clear EU Hurdle with Kenvue Asset Sales

Kimberly-Clark (KMB) is selling assets to address EU antitrust concerns over its $40B Kenvue acquisition, aiming for approval by September 29. The deal, expected to create a $32B revenue company, faces similar scrutiny in Australia. KMB anticipates $1.9B in annual cost synergies but may need to divest assets to secure approval.

yahoo.com2 min